Search filters

List of works by Maria Gkotzamanidou

Circulating angiopoietin-1 to angiopoietin-2 ratio is an independent prognostic factor for survival in newly diagnosed patients with multiple myeloma who received therapy with novel antimyeloma agents.

scientific article published on 30 May 2011

Diffuse pattern of bone marrow involvement on magnetic resonance imaging is associated with high risk cytogenetics and poor outcome in newly diagnosed, symptomatic patients with multiple myeloma: a single center experience on 228 patients

scientific article published on 28 May 2012

Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy.

scientific article published on 21 December 2011

Expression of CCL3 by Neoplastic Cells in Patients with Waldenström's Macroglobulinemia: An Immunohistochemical Study in Bone Marrow Biopsies of 67 Patients

scientific article published on 01 February 2011

Hematologic Response and Stabilization of Renal Function in a Patient With Light Chain Deposition Disease After Lenalidomide Treatment: A Novel Therapeutic Approach?

article

Increased expression of cyclin-D1 on trephine bone marrow biopsies independently predicts for shorter overall survival in patients with multiple myeloma treated with novel agents

scholarly article by Anna Tasidou et al published 6 May 2012 in American Journal of Hematology

Increased serum lactate dehydrongenase should be included among the variables that define very-high-risk multiple myeloma

scientific article published on 8 September 2011

Lenalidomide-associated pneumonitis in patients with plasma cell dyscrasias

scientific article published on 04 August 2011

Neutrophil Gelatinase--Associated Lipocalin and Cystatin C Are Sensitive Markers of Renal Injury in Patients With Multiple Myeloma

scientific article published on 3 November 2015

Renal impairment is not an independent adverse prognostic factor in patients with multiple myeloma treated upfront with novel agent-based regimens

scientific article

Response to bortezomib of a patient with scleromyxedema refractory to other therapies

article

Sclerostin: a possible target for the management of cancer-induced bone disease

scientific article published on 05 July 2012

Short progression-free survival predicts for poor overall survival in older patients with multiple myeloma treated upfront with novel agent-based therapy

The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: Final results on 205 patients of the Greek myeloma study group

scholarly article by Evangelos Terpos et al published 15 October 2013 in American Journal of Hematology

Paulina is supported by:

About Paulina

Help